Form 4: IDEAYA Biosciences Director Acquires Stock Options

IDEAYA Biosciences reports a Form 4 filing detailing the acquisition of stock options by Director Catherine J. Mackey.

Summary

• Catherine J. Mackey, a Director at IDEAYA Biosciences, Inc., acquired stock options on June 16, 2026.
• The options grant the right to buy 20,000 shares of common stock at an exercise price of $30.57 per share.
• These options are exercisable starting June 16, 2026, and expire on June 16, 2036.
• The vesting schedule indicates that 100% of the shares subject to the option will vest on the earlier of the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date, provided the Reporting Person remains in service on the Board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common practice for compensation and incentive alignment.

Positives

• Director Mackey's acquisition of stock options aligns her interests with shareholders, potentially indicating confidence in the company's future performance.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The vesting schedule for the stock options suggests a forward-looking incentive tied to continued service and company performance.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to attract and retain key talent and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with shareholder interests, potentially leading to decisions that enhance long-term value.
• Employees: Standard compensation practice that may be observed by other employees.
• Management: Reinforces standard compensation and incentive structures.

Next Steps

• Vesting of stock options based on the specified conditions.
• Potential exercise of stock options by Catherine J. Mackey.

Key Dates

Keywords

IDEAYA Biosciences, IDYA, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Catherine J. Mackey, Director